Objective: Current methods of risk-stratification in patients with type 2 diabetes are suboptimal. The current study assesses the ability of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (hs-cTnT) to improve the prediction of cardiovascular events and death in patients with type 2 diabetes.
assays, that can measure levels of troponin previously undetectable using 'conventional' assays, have been developed. (18, 19) Using such sensitive assays, detectable levels of cardiac troponin T have been reported in patients with stable coronary heart disease(20) and in a sizeable proportion of the general population, including those with no know cardiovascular disease. (21, 22) However, the ability of these sensitive assays to enhance risk prediction in patients with type 2 diabetes remains unclear.
We hypothesised that both NT-proBNP and high sensitivity cardiac troponin T (hs-cTnT) would predict major cardiovascular events and all-cause death in patients with type 2 diabetes and that these markers would provide prognostic information that was incremental to each other and to other widely accepted predictors of outcome.
METHODS
We performed a nested case-cohort study assessing the association between circulating levels of NT-proBNP and hs-cTnT and all-cause mortality and major cardiovascular events (a composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in regimen using modified release gliclazide, with a target HbA1c of ≤6.5% (48mmol/mol), versus standard, guideline based, glycemic control. The study was approved by the ethics committee for each participating centre and all participants provided written informed consent. Participants were ≥55 years of age and had been diagnosed with type 2 diabetes after the age of 30 years. In addition, they were required to have a history of cardiovascular disease or one or more additional cardiovascular risk factor.(25) Detailed study methods(25) and the main results(23,24) of the ADVANCE study have been previously reported.
Baseline data included demographic and clinical information. Weight, height, urinary albumin/creatinine ratio, serum creatinine, fasting lipid levels and glycated hemoglobin (HbA1c) were also measured at baseline. Plasma samples were obtained from all study participants at baseline and stored at -80 o C for a median of 7.8 years.
Samples were available from all countries involved in ADVANCE, except China and India, giving a total base population of 7,376. A random sub-cohort of 3,500 was selected from this base population for the case-cohort study, plus all additional individuals who had a cardiovascular event or died during follow-up (n=697). All outcomes were validated by an independent adjudication committee.
NT-proBNP and hs-cTnT were measured using electro-chemiluminescence immunoassays, performed on a Roche Elecsys 2010 automated platform (Roche Diagnostics, Burgess Hill, UK). The NT-proBNP assay has an effective measuring range of 5-30,000pg/mL.(26) The hs-cTnT assay has a lower detection limit of 3ng/L and in a healthy population the 99 th Page 6 of 35 Diabetes Care percentile level is ≥14ng/L.(19) Assays were performed using the manufacturer's calibrators and quality controls. NT-proBNP and hs-cTnT had assay coefficients of variation of 6.5% and 4.5% for the low control and 3.8% and 9.1% for the high control.
Statistical analyses
Categorical data are presented as number (percentage) and continuous data as mean (standard deviation), where symmetrically distributed, or median (inter-quartile range) where skewed.
Hazard ratios for a one standard deviation increase in each of NT-proBNP and hs-cTnT, after log transformation to remove effects of outliers, on cardiovascular events and death were obtained from weighted Cox regression models using the STSELPRE procedure for casecohort analyses (StataCorp Ltd, College Station, Texas) . Non-linearity was tested by comparing the deviances of linear and categorical models and by the inclusion of polynomial components (quadratic and cubic terms). Other analyses were performed using SAS v9.2 (SAS Institute, Cary, North Carolina). All p values reported are 2-sided, with the 5% threshold used to determine significance.
Three models, with different potential confounding variables, were fitted for each cardiac biomarker/outcome combination: model 1 with age, sex and randomized treatment; model 2 with, additionally, a prior macrovascular complication of diabetes (myocardial infarction, stroke, hospital admission for a transient ischemic attack or for unstable angina, coronary or peripheral revascularization or amputation secondary to peripheral vascular disease), duration of diabetes, current smoking, systolic blood pressure, body mass index, albumin/creatinine ratio, estimated glomerular filtration rate (eGFR), HbA1c, plasma glucose, total and HDL- history of heart failure, participation in moderate and/or vigorous exercise for >15 minutes at least once weekly and high-sensitivity C reactive protein; and model 3 with, additionally to model 2, the other biomarker (i.e. NT-proBNP or hs-cTnT). C-statistics for 5-year risk, accounting for censoring(27), were determined for the baseline clinical model (model 2 described above) and for this model plus each biomarker individually and in combination. In addition, the ability to discriminate and reclassify 5-year risk, using the integrated discrimination index (IDI) and the net reclassification improvement (NRI), were assessed by methods suitable for survival data, using bootstrapping.(28,29) NRI was derived using a continuous model for changes in risk classification, and from a categorical (or threshold) model based on 10%, 10-15%, and >15% risk.
RESULTS
The case-cohort study population comprised 4,197 patients. Blood samples for 335 (8%) participants were missing or unsuitable for analysis. Of the remaining 3,862 subjects, 709
(18%) experienced a major cardiovascular event during a median of 5 years follow-up (382 cardiovascular deaths, 238 non-fatal myocardial infarctions and 194 non-fatal strokes) and 706 (18%) died. The mean age of the study cohort was 67 years and 61% were male (table 1) .
The associations between categories of NT-proBNP and hs-cTnT and cardiovascular risk factors and known disease at baseline are shown in supplementary tables 1 and 2. Levels of NT-proBNP and hs-cTnT were moderately correlated (Spearman coefficient 0.40, p<0.001).
Sixty-two percent of ADVANCE study participants in the random sub-cohort had detectable (≥3ng/L) levels of hs-cTnT, including 58% of patients with no prior history of macrovascular disease.
There was a log-linear association between both biomarkers and both outcomes (pvalue<0.001) with no evidence of nonlinearity (p-value>0.05 for both markers and outcomes). After adjustment for age, sex and randomized treatment in the ADVANCE trial, both NT-proBNP and hs-cTnT were strong predictors of cardiovascular events and death (table 2) . These associations were only mildly attenuated after further adjustment for key clinical risk factors and other potential confounders. Even after additional adjustment for the other biomarker, each remained a strong predictor of both outcomes (table 2). These results were similar regardless of the age of the patient (≤ or >67 years, the median for the cohort), their sex or whether they did or did not have known macrovascular disease (figure 1a and figure 1b).
Both NT-proBNP and hs-cTnT significantly increased the c-statistic for the prediction of cardiovascular events and for death when compared to the baseline clinical model (table 3) .
In addition, a range of prediction metrics confirm that, even when all these clinical factors were taken into account, both markers greatly improved the ability to predict a cardiovascular event or death (table 3).
The increase in the c-statistic and improvements in the reclassification of risk were similar regardless of whether NT-proBNP or hs-cTnT was added to the baseline clinical model, whilst the combination of both provided better prognostic information (table 3). The addition 
Prior studies
The prognostic utility of NT-proBNP and B-type natriuretic peptide has been reported in patients with an acute coronary syndrome and those with heart failure. These markers also predict outcome in other settings, including community populations. (11) comprehensive adjustment for potential confounding factors, including both high sensitivity C reactive protein and hs-cTnT. More importantly, we have confirmed, to our knowledge for the first time, that levels of NT pro-BNP can considerably improve risk discrimination in patients with type 2 diabetes, suggesting that they may be of clinical value in this role.
Low levels of hs-cTnT, well below the threshold where they could be detected using a conventional assay, are commonly found in patients with stable coronary heart disease and/or heart failure and, in both settings, are strong predictors of adverse outcomes. between 30 and 65 years, 25% had hs-cTnT levels ≥3ng/L and 2% had levels ≥14ng/L. (21) Commensurate with these reports we found that 62% of our random sub-cohort of participants in ADVANCE had detectable (≥3ng/L) levels of hs-cTnT.
Only one prior study,(37) has previously assessed the prognostic utility of hs-cTnT in patients with diabetes. In 512 women with diabetes, and a mean age of 56 years, after adjustment for a range of clinical factors plus high sensitivity C-reactive protein and NT-proBNP, the presence of detectable hs-cTnT was associated with a 76% increase in the hazard of the composite end-point of cardiovascular death, myocardial infarction or stroke. (37) The confidence interval for the increased hazard was, however, wide (ranging from 0 to 308%) and the limited number of events preclude any more detailed assessment of the relationship between hs-cTnT elevation and outcome.(37) Likewise, the investigators were unable to assess the ability of hs-cTnT to reclassify risk. The ADVANCE data extend these findings;
confirming that hs-cTnT is a strong and independent predictor of major cardiovascular events 
Clinical implications of the current findings
Patients with type 2 diabetes are at considerable risk of vascular complications and have a high prevalence of, often asymptomatic, cardiovascular disease. Nevertheless, the risk of any individual may vary considerably and current methods to determine this have limitations.
Patients with type 2 diabetes mellitus are, therefore, a population where simple screening tests that could better detect those at highest risk would be of particular value. Our data suggest that levels of NT-proBNP and hs-cTnT may be useful adjuncts to clinical assessment and that both provide much more prognostic information than total cholesterol or high sensitivity C-reactive protein levels in this cohort. In addition, they have a complimentary prognostic role, such that the combination of both markers, along with clinical variables, maximises their predictive utility. It appears, however, that levels of NT-proBNP better capture the risk of cardiovascular events and death than levels of hs-cTnT.
Accurate risk-stratification allows treatments to be targeted to individuals who may derive particular benefit from interventions such as more intensive blood pressure lowering or statin therapy. Biomarkers might also identify a subgroup of patients who have the most to gain from anti-platelet therapy. These potential uses remain, however, untested. 
Strengths and limitations
The current study describes a cohort derived from a large population with diverse ethnic backgrounds, which was well-characterised and followed up closely. All end-points were independently adjudicated according to pre-defined criteria. Nevertheless, it has the limitations inherent in any post-hoc analysis. The study population were participants in a clinical trial and were eligible for this on the basis of having pre-existing cardiovascular disease or at least one cardiovascular risk factor in addition to diabetes. The results of the current study need, therefore, to be validated in an unselected community cohort.
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Although the large study population and case-cohort design ensures considerable statistical power, and allows reliable correction for many potential confounding factors, other possible confounders may be present. Levels of hs-cTnT and NT-proBNP were measured only once and the effects of serial changes in levels cannot be assessed. Likewise, we have no data on cardiac structure, function or perfusion so we cannot determine the mechanisms of the elevations observed.
Conclusion
In summary, our data suggest that, in patients with type 2 diabetes, levels of hs-cTnT and NT-proBNP greatly improve the accuracy with which the risk of cardiovascular events or death can be estimated and may be clinically useful in this role.
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Figure 1a
Hazard ratio Hazard ratio 95% CI P-value The characteristic of participants are presented in four categories of NT-proBNP levels, defined by their quartiles.
* participation in moderate and/or vigorous exercise for >15 minutes at least once weekly.SD, standard deviation; BMI, body mass index; ACE, angiotensin converting enzyme; HbA1c, hemoglobin A1c; ACR, albumin:creatinine ratio; eGRF, estimated glomerular filtration rate; hs-CRP, high sensitivity C-reactive protein, hs-cTnT, high sensitivity cardiac troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
